Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | CB25N1B | — |
inadvertent administration of only the prefilled syringe of the liquid MenB component of Penmenvy/ inappropriate reconstitution technique; it was only the liquid Men B portion that was administered to the patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 16-year-old male patient who received Men ABCWY NVS (Penmenvy) (batch number CB25N1B) for prophylaxis. On 16-MAR-2026, the patient received Penmenvy. On 16-MAR-2026, an unknown time after receiving Penmenvy, the patient experienced inappropriate preparation of medication (Verbatim: inadvertent administration of only the prefilled syringe of the liquid MenB component of Penmenvy/ inappropriate reconstitution technique) and inappropriate dose of vaccine administered (Verbatim: it was only the liquid Men B portion that was administered to the patient). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-MAR-2026 The general response center transferred an immunization program manager who asked for any advice or recommendation about the administration of only the liquid Meningococcal B portion of Penmenvy to a patient. The vaccine administration facility was the same as the primary reporter.